Dr. John Cush RheumNow
3 years 2 months ago
The Importance of Identifying Central Pain in PsA
Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy.
https://t.co/5fjNTrQvNx https://t.co/E1ivkK2bFz
Dr. John Cush RheumNow
3 years 2 months ago
Malignancy and CV Risk in Rheumatoid Arthritis
Dr. Jonathan Kay discusses OP0218, OP0219 and OP0211 at EULAR 2023 in Milan, Italy.
https://t.co/o5yrbCBaCb https://t.co/qptUCGb79q
Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease. At EULAR 2023, recommendations for imaging modalities for large vessel vasculitis were discussed. These were evidence-based recommendations adapted for practicality in clinical use.
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.
Dr. John Cush RheumNow
3 years 2 months ago
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks
Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy.
https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb
Dr. John Cush RheumNow
3 years 2 months ago
Daily Recap: Day One + Two
https://t.co/USBFbTWzGG https://t.co/RV9RyLLNmX
Dr. John Cush RheumNow
3 years 2 months ago
Abatacept: is there a role before RA hits?
Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy.
https://t.co/XJXabAULhn https://t.co/Hv93HKolKH
Dr. John Cush RheumNow
3 years 2 months ago
Among 247.3 million US adults. 10.0% (20.3 million) had CVD & 56% were at risk for CVD. Yet only 3.6 million CVD (18%) & 34.5 million at risk for CVD (26%) used wearable devices (compared to 29% in US adults, but less than half wear every day. https://t.co/04xqtkw61x https://t.co/ETTjamvHi2
Dr. John Cush RheumNow
3 years 2 months ago
Watch: Zoster Management and Vaccination
Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy.
https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x
At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.
In my focus group consisting of people living with SLE and their carers, one of the keys issues raised by them was pertaining to poor reliable information about their condition. At the 2023 EULAR Congress in Milan, I learned about the wide scale dissemination and international launch of Lupus100.org project.

